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BACKGROUND: The study of breast cancer in women with African ancestry offers the promise of identifying markers
for risk assessment and treatment of triple-negative disease. METHODS: African American and white American
women with invasive cancer diagnosed at the Henry Ford Health System comprised the primary study population,
and Ghanaian patients diagnosed and/or treated at the Komfo Anokye Teaching Hospital in Kumasi, Ghana consti-
tuted the comparison group. Formalin-fixed, paraffin-embedded specimens were transported to the University of
Michigan for histopathology confirmation, and assessment of estrogen and progesterone receptors and HER-2/neu
expression. RESULTS: The study population included 1008 white Americans, 581 African Americans, and 75 Ghana-
ians. Mean age at diagnosis was 48.0 years for Ghanaian, 60.8 years for African American, and 62.4 for white Ameri-
can cases (P¼.002). Proportions of Ghanaian, African American, and white American cases with estrogen receptor-
negative tumors were 76%, 36%, and 22%, respectively (P < .001), and proportions with triple-negative disease were
82%, 26%, and 16%, respectively (P < .001). All Ghanaian cases were palpable, locally advanced cancers; 57 (76%)
were grade 3. A total of 147 American women were diagnosed as stage III or IV; of these, 67.5% (n ¼ 46) of African
Americans and 44.6% (n=29) of white Americans were grade 3. Among palpable, grade 3 cancers, Ghanaians had
the highest prevalence of triple-negative tumors (82.2%), followed by African Americans (32.8%) and white Ameri-
cans (10.2%). CONCLUSIONS: Our study demonstrates progressively increasing frequency of estrogen receptor-nega-
tive and triple-negative tumors among breast cancer patients with white American, African American, and Ghanaian/
African backgrounds. This pattern indicates a need for additional investigations correlating the extent of African
ancestry and high-risk breast cancer subtypes. Cancer 2010;116:4926–32. VC 2010 American Cancer Society.
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Breast cancer, with an annual estimate of>180,000 new cases is the most common malignancy among women in the
United States.1,2 Because of the extensive effort and dedication of the research and medical community and different can-
cer advocacy organizations, significant milestones have been achieved in reducing the disease-specific mortality across dif-
ferent socioeconomic strata and racial/ethnic lines.3-6 Healthy People 2010, a national health promotion and disease
prevention initiative, has as 1 of its 2 main goals to eliminate health disparities across different segments of population.7
The notion of health disparities implies that the disease-specific risk for different subpopulations should be identified and
resources should be allocated accordingly.
African American women have a lower lifetime incidence of breast cancer compared with white American women,
yet they have higher breast cancer mortality rates.1 African American women are also more likely to be diagnosed with
breast cancer at younger ages, and with high-grade tumors that are negative for expression of the estrogen receptor (ER),
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progesterone receptor (PR), and the HER-2/neu
marker.8-10 Because these features are more common in
BRCA-1 mutation-associated breast cancer, it has been
postulated that African ancestry might be associated with
hereditary predisposition for high-risk breast cancer of a
specific subtype.11 The study of breast cancer in women
with African ancestry, therefore, has the potential for lead-
ing to the identification of biomarkers that might be use-
ful for the risk assessment and treatment of triple-negative
breast cancer. The University of Michigan has established
international breast cancer research collaboration with the
Komfo Anokye Teaching Hospital in Kumasi, Ghana,
and the Henry Ford Health System in Detroit, Michigan,
with the goal of studying the genetics of breast cancer in
African, African American, and white American women.
We report herein our initial findings with respect to com-
paring patterns of disease and selected clinicopathologic
features.
MATERIALS AND METHODS
The conduct of this study was approved by the institu-
tional review boards affiliated with the University of
Michigan in Ann Arbor, Michigan; the Henry Ford
Health System in Detroit, Michigan; and the Komfo
Anokye Teaching Hospital in Kumasi, Ghana.
Study Population
African American and white American women with inva-
sive breast cancer diagnosed through the Henry Ford
Health System between January 1, 2001 and December
31, 2007 comprised the primary study population.
Details regarding the Henry Ford Health System tumor
registry and data acquisition process have been reported
previously.12,13 Briefly, information on individual patient
demographics (self-reported race, date of birth) and breast
cancer clinicopathologic features (date of diagnosis, stage,
grade, expression of molecular markers estrogen receptor,
progesterone receptor, and HER-2/neu) were downloaded
from the Pathology Information System (Mysis-CoPath).
African women with invasive breast cancer diagnosed
and/or treated at the Komfo Anokye Teaching Hospital in
Kumasi, Ghana between January 1, 2007 and December
31, 2008 comprised the comparison group. Patient demo-
graphics and selected clinicopathologic features (age, tumor
size) were abstracted from the Komfo Anokye Teaching
Hospital hardcopy medical records and pathology reports.
Information regarding the extended medical history such as
menopausal status was rarely available, because hospital-
based financial limitations preclude the ability to maintain a
tumor registry or centralized medical records system. Fur-
thermore, image-guided wire localization biopsy procedures
are not available at Komfo Anokye Teaching Hospital, and
screening mammography is limited. All of the Ghanaian
breast cancer patients included in this study therefore pre-
sented with clinically evident disease. All breast cancers
from Komfo Anokye Teaching Hospital included in the
present analysis had formalin-fixed, paraffin-embedded
specimens transported to the University of Michigan
Department of Pathology, where they were recut, stained by
hematoxylin and eosin for histopathology confirmation,
and then stained by immunohistochemistry for ER, PR,
andHER-2/neu expression.
Assessment of ER and PR
Hormone receptor proteins in the nucleus of cells were
detected with specific monoclonal antibodies using a
labeled streptavidin-biotin immunoperoxidase method.
The immunocytochemical assay was performed on depar-
affinized formalin-fixed tissue sections of the specimens.
Monoclonal mouse antibodies to human ER (Dako
[Glostrup, Denmark] clone ID5) and to human PR
(Dako clone PgR636) were used with a Dako automated
immunostainer following the manufacturer’s protocol.
Slides were then reviewed using light microscopy, and the
percentage of cells with nuclear immunoreactivity was
semiquantitatively assessed. Slides were graded as positive,
negative, or focal positive, indicating a lower level of re-
ceptor protein.14,15 For the purpose of the present study,
the status of ER and PR was dichotomized as positive or
negative. Therefore, cells with focal positive status for ER
and/or PR were classified as positive.
Assessment of HER-2/neu
Fluorescent in situ hybridization (FISH) and immunohis-
tochemistry (IHC) were used to assess amplification of
the HER2 gene and overexpression of its protein, p185,
respectively. IHC was performed on formalin-fixed,
paraffin-embedded tissue sections using the HerceptTest
(Dako) according to the manufacturer’s instructions. The
Dako HerceptTest is a US Food and Drug Administra-
tion-approved clinical test that qualitatively identifies by
light microscopy p185 HER2 overexpression in breast
cancer cells. The relative expression of HER2 was scored
as either 1þ or weakly positive (staining in <10% of tu-
mor cells), 2þ or weak to moderate positive (complete
membrane staining in >10%), or 3þ or strongly positive
(strong complete membrane staining in >10%).
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Specimens that were scored as 2þ were further evaluated
by the FISH technique. The method was performed on
formalin-fixed, paraffin-embedded tissue sections using a
DNA probe cocktail specific for the HER-2/neu gene
locus (17q11.2-q12) and an internal control probe for
chromosome 17 (CEP17-D17Z1) (Vysis, Downers
Grove, Ill). After hybridization cells were scored, the ratio
of HER-2/neu to CEP17 was calculated. A ratio of >2
was considered as positive for amplification. For the pur-
pose of the present study, HER-2/neu status was dicho-
tomized as either positive or negative. A specimen scored
as 0 was classified as HER-2/neu negative; a specimen was
considered positive if it received an IHC score of 3þ. For
specimens with an IHC score of either 1þ or 2þ, an ampli-
fication ratio of >2 was classified as positive for HER-2/
neu, a ratio2 was considered negative.
Definition of Subtypes of Breast Carcinoma
Presently, application of DNAmicroarray technology is not
readily available in many clinical settings. IHC and/or FISH
provide valid, reliable, and cost-effective methods for evalu-
ation of prognostic biomarkers.16 Reproducible correlation
of IHC with microarray technique supports the validity of
IHC for the purpose of subtyping of breast carcinoma.17 In
addition, hormone receptors and HER-2/neu status are the
primary biomarkers for subtyping.18,19 For the purpose of
the present study, we adopted an IHC classification that cat-
egorizes breast carcinoma according to the expression status
of ER, PR, andHER-2/neu.
Statistical Methods
Prevalence distribution of categorical data, ER, PR, HER-
2/neu, histologic grade, and histopathology of cancer
among the 3 groups of women was evaluated using the
Kruskal-Wallis test. Analysis of variance with Tukey post
hoc test of significance was applied to compare the loca-
tion of mean values for the 2 continuous variables, age at
the time of diagnosis and tumor size in the greatest dimen-
sion, among the 3 groups of women. All statistical com-
parisons were 2-sided, and analysis were performed using
SAS v. 9.1 (SAS Institute, Cary, NC).
RESULTS
A total of 1008 white American, 581 African American, and
75 Ghanaian women contributed to this study. The mean
age at the time of the diagnosis for Ghanaian women was
48.0 years (6.4 years) compared with 60.7 years (13.7
years) for African American women and 62.4 years (13.7
years) for white American women (P= .0019). (Table 1) All
of the Ghanaian women had palpable cancers that were
diagnosed by clinical breast examination followed by subse-
quent pathologic confirmation via freehand (ie, without
image guidance) percutaneous core needle biopsy (1=3) or
surgical resection (2=3). Mean primary breast tumor size for
the Ghanaian, African American, and white American
women was 3.20 cm, 2.3 cm, and 1.95 cm, respectively (P
< .001). Approximately 75% (n =56) of the Ghanaian
cases were grade 3 lesions. Data for histologic grade were
available for a total of 828 white American and 450 African
American women. Of these women, 44.9% (n= 202) of
African American and 29.3% (n =243) of white American
women were presented with grade 3 cancers (Table 1).
A total of 57 (76%) Ghanaian women were diag-
nosed with ER-negative cancers. Data on the status of PR
and HER-2/neu biomarker were available for a total of 48
women, of whom 66.7% (n = 32) were diagnosed with
PR-negative and 95.8% (n ¼ 46) with HER-2/neu–
Table 1. Comparisons of Clinicopathologic Features in Study Populations
Feature HFH WA,a n=1008 HFH AA,b n=581 Ghanaian,c n=75 P
Mean age, y (SD) 62.4 ( 13.7) 60.7 ( 13.7) 48.0 ( 6.4) .002
Mean tumor size, cm (range) 1.95 (0.1-14.0) 2.30 (0.1-15.0) 3.20 (0.9-9.0) <.001
Histology (% with invasive ductal carcinoma) 821/1008 (81.4) 499/581 (86) 50/75 (66.7) <.0001
Grade 3 (%) 243/828d (29.3) 202/450d (44.9) 57/75 (76) .007
ER (%) 218/995d (21.9) 208/576d (36.1) 57/76 (76) <.0001
PR (%) 249/827d (30.1) 199/443d (44.9) 32/48d (66.7) .0001
HER-2/neu (%) 641/836d (76.7) 332/442d (75.1) 46/48d (95.8) .0001
ER, PR, HER2 (%) 122/763 (16.0) 107/405 (26.4) 37/45 (82.2) .0001
ERþ and/or PRþ, HER2 (%) 472/763 (61.9) 200/405 (49.4) 6/45 (13.3) .019
HFH indicates Henry Ford Health System; WA, white American; AA, African American; SD, standard deviation; ER, estrogen receptor; progesterone receptor.
aWA breast cancer cases from the HFH.
bAA breast cancer cases from the HFH.
cGhanaian women from Komfo Anokye Teaching Hospital in Kumasi, Ghana.
dMissing data.
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negative breast cancers (Table 1). Data on the status of
ERs were available for 995 white American and 576 Afri-
can American women. The prevalence of ER-negative
cancer was 21.9% (n = 218) in white American and
36.1% (n = 208) in African American women. We were
able to retrieve PR data for a total of 827 white American
and 443 African American women. Twenty-nine percent
(n = 249) of white American and 43.4% (n = 199) of Afri-
can American women were diagnosed with cancer lacking
the expression of PRs. Finally, data for HER-2/neu bio-
marker were available for a total of 836 white American
and 442 African American women. More than 3=4
(76.7%; n = 641) of white American women and 75.1%
(n = 332) of African American women were diagnosed
with HER-2/neu–negative breast cancer (Table 1). We
then classified the 3 groups of women by the joint expres-
sion of the 3 diagnostic biomarkers (ER, PR, and HER-2/
neu). We observed the highest prevalence of triple-nega-
tive breast cancers in Ghanaian women (82.2%, n = 37),
followed by African American (26.4%, n = 107) and white
American (16.0%, n = 122) women. In contrast, the high-
est proportion of women diagnosed with ERþ and/or
PRþ, HER2 breast cancers was observed in white Ameri-
can women (61.9%, n = 472), followed by African
American (49.4%, n = 200) and Ghanaian (13.3%, n = 6)
women. (Table 1).
To minimize the potential confounding effect of
advanced stages and poorly differentiated grades, we
stratified American women by their stage and grade of
cancers and estimated the prevalence of hormone recep-
tor-negative breast cancers. A total of 28 (2.8%) white
American women, 46 (7.9%) African American women,
and 57 (76%) Ghanaian women were diagnosed with
poorly differentiated and advanced stage (III/IV) breast
cancer (Table 2). Absence of expression of ERs was
observed in 77.2% (n = 44) of Ghanaian women, 67.4%
(n = 31) of African American women, and 50.0% (n = 14)
of white American women (P = .043). Interestingly, Afri-
can American women had the highest prevalence of PR-
negative cancers (76.1%, n = 35), followed by Ghanaian
(69.2%, n = 27) and white American (60.7%, n = 17)
women (P = .297). Finally, 94.7% (n = 36) of Ghanaian
women were diagnosed with HER-2/neu–negative breast
cancer, compared with 63.0% (n = 29) of African Ameri-
can women and 46.4% (n = 13) of white American
women (P< .0001) (Table 2). We then stratified women
by the joint expression of ER, PR, and HER-2/neu bio-
marker (Fig. 1). Eighty-three percent (n = 30) of Ghana-
ian women were diagnosed with triple-negative breast
cancer, whereas the proportion of African American
women with triple-negative breast cancer was 41.9%
Table 2. Comparisons of Clinicopathologic Features in Study Populations Subsets With Advanced








Estrogen receptor negative (%) 14/28 (50.0) 31/46 (67.4) 44/57 (77.2) <.041
Progesterone receptor negative (%) 17/28 (60.7) 35/46 (76.1) 27/39d (69.2) .374
HER-2/neu negative (%) 13/28 (46.4) 29/46 (63.0) 36/38d (94.7) <.0001
HFH indicates Henry Ford Health System; WA, white American; AA, African American.
aWA breast cancer cases from the HFH.
bAA breast cancer cases from the HFH.
cGhanaian women from Komfo Anokye Teaching Hospital in Kumasi, Ghana.
dMissing data.
Figure 1. Prevalence is shown of selected subtypes among
white American, African American, and Ghanaian women
diagnosed with palpable cancers and poorly differentiated
histologic grade. Frequencies shown are for hormone recep-
tor-negative, HER-2/neu-positive, and triple-negative breast
cancer subtypes. Data for frequencies of estrogen receptor
(ER)-positive/progesterone receptor (PR)-positive/HER2-
positive and ER-positive/PR-positive/HER2 negative tumors
are not shown. WA indicates white American; AA, African
American.
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(n = 18) and of white American women was 15.4%
(n = 4). In contrast, white American women experienced
the highest proportion (38.5%, n = 10) of hormone-inde-
pendent, HER-2/neu–positive breast cancer, followed by
African American (30.2%, n = 13) and Ghanaian women
(2.8%, n = 1).
We also stratified African American and white
American women by their menopausal status and com-
pared frequencies of triple-negative breast cancers. Among
premenopausal African American and white American
women, the prevalence of triple-negative breast cancer
was 32.3% and 25.2%, respectively. These proportions
were significantly lower than the 82% triple-negative rate
observed among the Ghanaian cases, the majority of
whom were younger than the commonly used menopau-
sal surrogate cutpoint of 50 years. Non–triple-negative
tumors were rare among Ghanaian cases, regardless of
age.
DISCUSSION
Lifetime breast cancer incidence rates are lower for African
American women, yet mortality rates are paradoxically
higher. The mortality differences mostly can be explained
by the more advanced stages at the initial clinical presenta-
tion of the disease that is observed for African American
breast cancer patients, and this in turn, although multifac-
torial, is likely driven by delays in diagnosis and treatment
that result from the poverty rates and healthcare access
barriers that are more prevalent in the African American
patient population.
Several of the other features that describe the breast
cancer burden of the African American community are
more enigmatic and not readily explained by socioeco-
nomic factors. For example, African American women are
more likely to develop breast cancer at younger ages. In
addition, at any age of diagnosis they are more likely to
have aneuploidy and tumors that are negative for ER, PR,
and the HER-2/neumarker. In Table 3, we have provided
summary data from selected studies that have compared
the frequency of triple-negative breast cancers between
African American and white American women.8,13,20-23
These molecular marker patterns suggest that outcome
disparities are likely to increase over the next few years,
because the most significant recent advances in systemic
therapy for breast cancer have been made in the manage-
ment of endocrine-sensitive and/or HER-2/neu–overex-
pressing disease. Fewer African American women will be
candidates for these treatment advances. Lastly, the inci-
dence of male breast cancer is also higher for African
American compared with white American commun-
ities.24,25 All of these latter features describing African
American breast cancer also serve to describe the breast
cancer burden of patients with known hereditary suscepti-
bility, such as carriers of BRCA1 mutations. It has also
been well documented that selected BRCA mutations
(founder mutations) are particularly common within spe-
cific populations defined by ancestral heritage (such as the
Ashkenazi Jewish community).26-28 It is therefore reason-
able to explore the possibility that African ancestry might
also be associated with some hereditary predisposition for
early onset or high-risk breast cancer. Extent of African
background can be quite variable in individuals who self-
Table 3. Frequency of Reported Triple-Negative Breast Cancer in AA and WAWomen
Study Dataset/Sample Size Frequency of TN or Basal Subtype Breast Cancer
AAs WAs P
Carey 20068 97 premenopausal AA vs 164 premenopausal
non-AA women from Carolina Breast
Cancer Study
39% (basalAU: Please note asterisks





Morris 200720 2230 Thomas Jefferson University Hospital
pts and 197,274 SEER pts
20.8% (TN) 10.4% (TN) <.0001
Stark 200813 Henry Ford Health System, 441 AA, 822 WA 24.4% (TN) 14.4% (TN) <.0001
Lund 200821 167 AA and 23 WA cases from Grady
Hospital; urban Atlanta, GA
29.3% (TN) 13.0% (TN) .05
Moran 200822 99 AA and 968 WA breast conservation pts
from Yale University School of Medicine
21% (TN) 8% (TN) <.0001
Lund 200923 Population-based Atlanta GA cohort of 116
AA, 360 WA cases
46.6% (TN) 21.8% (TN) <.001
AA indicates African American; WA, white American; TN, triple negative; pts, patients; SEER, Surveillance, Epidemiology, and End Results.
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identify as African American because of the past 4 centu-
ries of genetic admixture that has occurred in the United
States. However, it can generally be assumed that extent
of African ancestry is likely to be stronger for individuals
who self-identify as African American compared with
those who self-identify as white American, but not as
strong as that seen in contemporary populations residing
in continental Africa.
This article represents the first published study that
directly compares clinicopathologic features of a contem-
porary African breast cancer population (as represented in
Ghana) with those of white American and African Ameri-
can breast cancer patients diagnosed within a similar
timeframe. Ghana is a particularly valuable comparison
population, because of its geographic location in western,
sub-Saharan Africa, where many of the colonial-era slave
colonies were also located. It is therefore a reasonable ex-
pectation that contemporary African American and con-
temporary Ghanaians have some shared ancestry. Other
studies of breast cancer in selected African populations
have demonstrated similarly high prevalence of ER-nega-
tive and triple-negative tumors.29,30
Our study documented provocative patterns of
increasing frequency for early onset/younger age at diag-
nosis, ER-negative/PR-negative, and triple-negative breast
cancers in association with presumed increasing extent of
African ancestry. These patterns suggest that further study
of the breast cancer burden in African women could lead
to the identification of tumor or germline markers
associated with high-risk breast cancer. Hopefully, these
markers will ultimately have potential utility for targeted
therapy of the triple-negative phenotype, for which we are
currently limited to chemotherapy as systemic treatment.
This study has several obvious limitations. First, the
younger average age at diagnosis for Ghanaian breast can-
cer patients may well be influenced by the overall shorter
longevity expectations in developing countries. Average
lifespan for Ghanaians is approximately 20 years younger
than the average life expectancy of 77 years for Americans.
Also, it has been suggested that racial/ethnic identity is
confounded by the stronger effect of poverty as an inde-
pendent risk factor for ER-negative disease.31 However,
data from international registries (in countries that have
more homogeneous populations and therefore less oppor-
tunity for confounding between race/ethnicity and socioe-
conomic factors) fail to show any consistent association
between poverty and frequency of ER-negative breast can-
cer.32-34 Furthermore, our study is notably limited by the
paucity of detailed clinicopathologic information on the
Ghanaian breast cancer cases. We were therefore unable to
perform any stratified comparisons based on menopausal
status or disease stage beyond the subset analyses of cases
with palpable tumors. This is of particular concern because
the argument could be made that the high frequency of
ER-negative disease among African women is a direct con-
sequence of the fact that few Ghanaian women have access
to screening mammography, and so the majority of breast
cancer patients present with ER-negative tumors that were
rapidly growing. Population-based data from the Surveil-
lance, Epidemiology, and End Results (SEER) program
refutes this argument, at least as it pertains to African
American women. The SEER program documents higher
population-based incidence rates for ER-negative breast
cancers in African American compared with white Ameri-
can women at all age categories, and regardless of whether
the cancer is diagnosed as locally advanced, nonlocally
advanced, or inflammatory disease.35,36 Lastly, we have
made the assumption that many African American women
are likely to have shared ancestry with many Ghanaian
women, because of the slave trade colonies located in west-
ern, sub-Saharan Africa. However, we did not have any
data on the actual geographic ancestry for the African
American women included in this study. We therefore do
not know the relative contributions of East African versus
West African or other geographically defined communities
to their lineage.
In summary, we report herein a correlation between
risk of ER-negative and triple-negative breast cancer and
presumed extent of African ancestry by looking at White
American, African American, and African breast cancer
patients. Our findings underscore the need for further research
regarding the breast cancer burden of African women.
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